(Q36716739)

English

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

scientific article published on 24 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

phase II clinical trial

0 references

0 references

lenvatinib mesylate

1 reference

ChEBI release 2020-05-28

differentiated thyroid carcinoma

1 reference

based on heuristic

inferred from title

Barbara Jarząb

3

object named as

Barbara Jarzab

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Steven I. Sherman

object named as

Steven I Sherman

19

0 references

object named as

Lisa F Licitra

18

0 references

Rossella Elisei

object named as

Rossella Elisei

16

0 references

Duncan J Topliss

object named as

Duncan Topliss

10

0 references

6

object named as

Bruce Robinson

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Maria E Cabanillas

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Martin Schlumberger

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Renato G Martins

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Furio Pacini

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Judith C McCaffrey

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Manisha H Shah

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Donald L Bodenner

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Corina Andresen

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

James P O'Brien

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Min Ren

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yasuhiro Funahashi

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Roger Allison

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kate Newbold

17

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Douglas W Ball

20

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

24 April 2015

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

121

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

16

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2749-2756

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

The impact of age and gender on papillary thyroid cancer survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Approach to the patient with advanced differentiated thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Targeted therapies for thyroid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Targeting the ANGPT-TIE2 pathway in malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Cytotoxic chemotherapy for differentiated thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Resistance to targeted therapy in renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Phase II trial of sorafenib in metastatic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Motesanib diphosphate in progressive differentiated thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Angiogenesis as a therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Management of thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

30 September 2017

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

5 September 2018

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

5 September 2018

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

5 September 2018

Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4803478

5 September 2018

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.29395

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.29395

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36716739&oldid=2038642094"